For millions of adults living with a condition that quietly erodes lung function year by year, clinical care has long been inconsistent — driven more by physician habit than evidence. A new set of practice guidelines from a leading pulmonary medicine authority may begin to close that gap, offering the first systematically graded framework for managing adult bronchiectasis across its most clinically consequential decision points.
An expert panel convened by the American College of Chest Physicians (ACCP) synthesized evidence from 47 studies, addressing eight structured clinical questions using the GRADE methodology — the gold standard for evaluating certainty of evidence in guideline development. The resulting 13 recommendations span the full management spectrum: antibiotic selection and duration for acute exacerbations, oral versus inhaled versus intravenous antibiotic routes, long-term suppressive antibiotic regimens, anti-inflammatory therapy strategies, airway clearance techniques, management of hemoptysis, and criteria for considering surgical resection. Crucially, all 13 recommendations are designated conditional, reflecting the underlying evidence base — predominantly observational studies and smaller randomized trials — rather than the high-certainty randomized controlled trial data that would support strong directives.
The conditional grading is telling. Bronchiectasis remains a field where evidence quality consistently lags behind clinical need. Unlike COPD or asthma, bronchiectasis has historically attracted less pharmaceutical investment, leaving clinicians to extrapolate from heterogeneous populations and single-center cohorts. These guidelines do not resolve that evidence deficit — they map it. The explicit GRADE-based transparency means clinicians and patients can see precisely where recommendations rest on solid ground and where they do not. For a condition marked by significant heterogeneity in etiology, microbiology, and severity, that epistemic honesty matters. The practical implication for health-conscious adults is that bronchiectasis management is entering a more standardized era, even if the evidence base still demands continued investment in large, well-powered multicenter trials.